Metraipolis › archive › dc_70a9519062ea

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a… — Europe PMC PMID:41727549

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41727549
DOI
10.3389/fphar.2026.1644757
License (as archived)
solo-consultazione
Archived
2026-11-06T01:45:53.688Z
SHA-256 of the archived text
a079b4b61ed4ebfad487c99d8941f0611df41d12268f5b95f59dd9f9e0134173
Stable URL of this page
https://metraipolis.com/documento/dc_70a9519062ea

How to cite

Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a… — Europe PMC PMID:41727549 — Europe PMC (en), https://europepmc.org/article/MED/41727549 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_70a9519062ea (Metraipolis archive dc_70a9519062ea, sha256 a079b4b61ed4ebfad487c99d8941f0611df41d12268f5b95f59dd9f9e0134173)
BibTeX
@misc{dc70a9519062ea,
  title = {Differential cardiovascular benefits of SGLT2 inhibitors, sacubitril/valsartan, omecamtiv mecarbil, and vericiguat across heart failure phenotypes: a… — Europe PMC PMID:41727549},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41727549},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_70a9519062ea; sha256 a079b4b61ed4ebfad487c99d8941f0611df41d12268f5b95f59dd9f9e0134173},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41727549. Agents can read the archived copy with the MCP tool read_document.